Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company's Next Generation COVID-19 Vaccine

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older Higher efficacy was observed in mRNA-1283 compared to Spikevax…

Health

Welcome to /f/health! This blurb is dedicated to all aspects of well-being. Join discussions on physical and mental health, nutrition, fitness, and medical advancements. Our rules: 1. Be respectful. 2. Stay on topic. 3. Provide reliable sources. 4. Avoid medical advice. 5. No self-diagnosis or promotion. Engage in informed discussions and explore the world of health with us!

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company's Next Generation COVID-19 Vaccine - Moderna Investor Relations

Comments